Tumor size, lymph node involvement, and Bax/Bcl-2 ratio were also higher in advance-stage tumors in our study, which may suggest that Bax/Bcl-2 ratio levels are associated with OSCC aggressiveness. The gene discussed is BCL2; the disease is neoplasm.